A pre-vaccine biomarker may flag weak vaccine responders, with sharpest stakes for the immunocompromised

Two patients of the same age and health walk into a clinic for the same vaccine. One walks out protected. The other does not. A new study from Arizona State University's Biodesign Institute suggests the difference may be partly readable in their blood, before either gets the shot. The finding lands with the most weight for people whose immune systems are already compromised, who face the sharpest exposure to the gap between getting a vaccine and having it work.

Researchers profiled blood samples from 4,000 people, healthy volunteers and immunosuppressed patients alike, against 185 antigens drawn from common viruses, bacteria, and targets associated with autoimmune disease. They asked a machine-learning model to find patterns in those pre-vaccination profiles that lined up with each donor's antibody response after COVID-19 vaccination. The patterns that emerged did something researchers have long chased: separate strong responders from weak ones using only a blood draw taken before the shot. (ASU News)

The team called these predictive profiles "sentinel antibodies," a coined name for a research-stage concept, not a clinical category. In the paper, published in Cell Press Blue under the title "Pre-vaccine sentinel antibodies predict blunted vaccine responses," the authors describe pre-existing antimicrobial antibody profiles as "scalable biomarkers of humoral immune responsiveness" and a framework for predicting vaccine response before immunization.

The mechanism matters because it is not genetic. Many proposed predictors of vaccine response, from HLA type to cytokine signaling, depend on assays a routine clinic does not run. Antibody patterns against common microbes can in principle be measured from a standard blood draw, which is what makes a future forecasting test even plausible.

"Certain biomarkers, when analyzed with AI, can predict who is likely to respond well to a vaccine, even before they receive it," LaBaer said. "Some people may be more immune-ready than others." (Genetic Engineering & Biotechnology News)

Vaccine response heterogeneity has well-documented drivers: age, sex, genetics, prior illness, and underlying health conditions. Immunocompromised patients typically sit at the weak end of that distribution, which is why boosters, alternate schedules, and post-vaccine titer checks are already part of their care. A pre-vaccine biomarker would not change which vaccines they receive, but it could let clinicians flag patients who need extra monitoring or adjusted timing before the first dose, rather than after a failed response.

The 4,000-person sample was profiled for COVID-19 vaccine response specifically, and the predictive patterns will need validation in larger and more diverse populations before any panel moves from paper to clinic. No commercial test exists, and no professional society has recommended routine pre-vaccine antibody-pattern screening. The paper frames itself as biomarker discovery, not clinical deployment. (News-Medical.net)

What the study does offer is a candidate explanation for why two people of similar age and health can have very different outcomes from the same vaccine, and a candidate handle for measuring that gap before it matters. Coverage so far has leaned on the AI angle; the practical question for clinicians and patients is whether the antibody-pattern signal holds up in the next cohorts. (Discover Magazine)